Clinical Progress on Bortezomib in the Treatment for Multiple Myeloma

Bortezomib is a new proteasome inhibitor. Clinical studies demonstrat that bortezomib plays role in the treatment for relapsed, refractory and initially treated multiple myeloma. Clinical progress on bortezomib in the treatment for multiple myeloma was reviewed.